从轻中度到重度哮喘:NORDSTAR队列的风险因素与患者特征
4.1%进展为重度哮喘;中剂量ICS下仍发作、血嗜酸粒细胞≥0.6×10^9/L等为风险因素。特定高危特征患者5年进展风险达30.4%。
要点
- 首次急性发作后5年内仅4.1%进展为重度哮喘,总体风险低。
- 中剂量ICS下仍发作(OR=3.72)和血嗜酸粒细胞≥0.6×10^9/L(OR=1.97)为强风险因素。
- 40-49岁晚发嗜酸粒细胞性哮喘、中剂量ICS且反复呼吸道感染患者5年风险达30.4%。
核心结论
- 轻中度哮喘首次急性发作后5年内进展为重度哮喘的比例为4.1%,但特定高危特征患者风险可达30%。
研究设计与样本
- 采用多变量logistic回归评估基线风险因素,并按特定患者特征评估进展风险。
主要发现
- 基线年龄40-49岁OR=1.62(95%CI 1.49-1.77)。
- 中剂量ICS下仍发作OR=3.72(95%CI 3.39-4.09)。
- 高剂量短效β2受体激动剂使用OR=1.76(95%CI 1.64-1.90)。
- ≥2次呼吸道感染OR=1.61(95%CI 1.49-1.73);血嗜酸粒细胞≥0.6×10^9/L OR=1.97(95%CI 1.47-2.61)。
关键数值与推荐
- 重度哮喘定义依据欧洲呼吸学会(ERS)/美国胸科学会(ATS)指南。
- 40-49岁晚发嗜酸粒细胞性哮喘、中剂量ICS治疗且反复呼吸道感染患者5年进展风险为30.4%。
临床怎么用
- 对轻中度哮喘首次急性发作患者,应评估年龄、ICS剂量下发作情况、SABA使用、呼吸道感染史及血嗜酸粒细胞计数以识别高危人群。
- 具备多个风险因素的高危患者5年进展风险可达30%,或需加强监测与早期干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The progression from mild-to-moderate to severe asthma remains unclear. This study aimed to assess the risk of progression following the first asthma exacerbation in mild-to-moderate asthma and to identify risk factors and high-risk patient profiles. METHODS: This was an observational cohort study based on Danish data from the Nordic Dataset for Asthma Research collaboration platform. Adult patients with mild-to-moderate asthma experiencing their first asthma exacerbation were identified between 2000 and 2018 and followed prospectively for 5 years for the development of severe asthma according to European Respiratory Society (ERS) / American Thoracic Society (ATS) guidelines. Baseline risk factors for progression to severe asthma were assessed using multivariable logistic regression models, and risk of progression was evaluated across specific patient profiles. RESULTS: Among 99 748 patients with mild-to-moderate asthma experiencing the first asthma exacerbation, 4.1% progressed to severe asthma within 5 years. Risk factors included baseline age 40-49 years (odds ratio [OR] = 1.62; 95% CI, 1.49-1.77), experiencing an exacerbation despite medium-dose inhaled corticosteroid (ICS) use (OR = 3.72; 95% CI, 3.39-4.09), high use of short-acting beta agonist (OR = 1.76; 95% CI, 1.64-1.90), ≥2 respiratory infections (OR = 1.61; 95% CI, 1.49-1.73), and blood eosinophil counts ≥ 0.6 × 109/L (OR = 1.97; 95% CI, 1.47-2.61). A patient aged 40-49 years with late-onset eosinophilic asthma, treated with medium-dose ICS and with recurrent respiratory infections, had a 30.4% 5-year risk of progressing to severe asthma. CONCLUSION: In patients with mild-to-moderate asthma experiencing their first asthma exacerbation, few (4.1%) patients overall progressed to severe asthma within 5 years, but specific high-risk patient profiles faced risks of up to 30%. Whether early recognition can modify this risk warrants further investigation.
引用
- Hansen, von Bülow, Cooper, et al. From mild-to-moderate to severe asthma: risk factors and patient profiles from the NORDSTAR cohort. Am J Respir Crit Care Med. 2026. PMID: 42133832. doi:10.1093/ajrccm/aamag242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。